ITMI990375A1 - Trattamento del cancro co epotiloni - Google Patents

Trattamento del cancro co epotiloni

Info

Publication number
ITMI990375A1
ITMI990375A1 IT99MI000375A ITMI990375A ITMI990375A1 IT MI990375 A1 ITMI990375 A1 IT MI990375A1 IT 99MI000375 A IT99MI000375 A IT 99MI000375A IT MI990375 A ITMI990375 A IT MI990375A IT MI990375 A1 ITMI990375 A1 IT MI990375A1
Authority
IT
Italy
Prior art keywords
hepotylon
cancer treatment
cancer
treatment
hepotylon cancer
Prior art date
Application number
IT99MI000375A
Other languages
English (en)
Italian (it)
Inventor
Reilly Terence O'
Markus Wartmann
Manuel Litchman
Pamela Cohen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ITMI990375A1 publication Critical patent/ITMI990375A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IT99MI000375A 1998-02-25 1999-02-24 Trattamento del cancro co epotiloni ITMI990375A1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Publications (1)

Publication Number Publication Date
ITMI990375A1 true ITMI990375A1 (it) 1999-08-25

Family

ID=27517450

Family Applications (1)

Application Number Title Priority Date Filing Date
IT99MI000375A ITMI990375A1 (it) 1998-02-25 1999-02-24 Trattamento del cancro co epotiloni

Country Status (10)

Country Link
US (4) US6635666B2 (https=)
EP (1) EP1056453B1 (https=)
JP (1) JP2002504511A (https=)
AU (1) AU755944B2 (https=)
BE (1) BE1011980A5 (https=)
CA (1) CA2319752A1 (https=)
FR (1) FR2775187B1 (https=)
IT (1) ITMI990375A1 (https=)
NZ (1) NZ506187A (https=)
WO (1) WO1999043320A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU3606700A (en) * 1999-02-26 2000-09-14 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
EP1154779A2 (en) * 1999-02-26 2001-11-21 Napro Biotherapeutics, Inc. Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HU229349B1 (en) * 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
PL363363A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
SK287334B6 (sk) * 2001-03-19 2010-07-07 Novartis Ag Kombinácia protihnačkového činidla a epotilónu alebo jeho derivátu, farmaceutická kompozícia a obchodné balenie, ktoré ju obsahujú, a jej použitie
MXPA03010909A (es) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE60330407D1 (de) * 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
BRPI0314133A8 (pt) 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
WO2004052361A1 (en) * 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
AR052142A1 (es) * 2004-11-18 2007-03-07 Bristol Myers Squibb Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
JP2009536153A (ja) * 2006-04-05 2009-10-08 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
WO2008061192A2 (en) * 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized maml peptides and uses thereof
WO2008154709A1 (en) 2007-06-20 2008-12-24 Saluc Technologies S.A. Convertible dining / billiard table
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9862692B2 (en) * 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US253697A (en) * 1882-02-14 John halley and alexandee baee
US34452A (en) * 1862-02-18 Improvement in railroad joints or chairs
US127432A (en) * 1872-06-04 Improvement in tuckers for sewing-machines
US203876A (en) * 1878-05-21 Improvement in piston water-meters
US142990A (en) * 1873-09-23 Improvement in machines for burnishing the shanks of boots and shoes
US203938A (en) * 1878-05-21 Improvement in wire fences
US260098A (en) * 1882-06-27 Rolls for longitudinally slitting railroad-rails
US220295A (en) * 1879-10-07 Improvement in hinges
US176429A (en) * 1876-04-25 Improvement in nut-locks
US87634A (en) * 1869-03-09 Improvement in grain-storehouses
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2167201A1 (en) * 1993-07-15 1995-01-26 Pfizer Inc. Amide derivatives of 16-membered ring antibiotic macrolides
DK1186606T4 (da) * 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) * 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
SK287775B6 (sk) 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6121029A (en) * 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
NZ508326A (en) 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
DE19848306A1 (de) * 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
EP1652926B1 (en) 2000-04-28 2009-09-30 Kosan Biosciences, Inc. Crystalline epothilone d
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof

Also Published As

Publication number Publication date
US6635666B2 (en) 2003-10-21
CA2319752A1 (en) 1999-09-02
JP2002504511A (ja) 2002-02-12
FR2775187B1 (fr) 2003-02-21
EP1056453B1 (en) 2010-10-06
US20050165071A1 (en) 2005-07-28
EP1056453A1 (en) 2000-12-06
AU755944B2 (en) 2003-01-02
FR2775187A1 (fr) 1999-08-27
US7875601B2 (en) 2011-01-25
NZ506187A (en) 2003-11-28
WO1999043320A1 (en) 1999-09-02
US7091226B2 (en) 2006-08-15
US20040024033A1 (en) 2004-02-05
AU2927999A (en) 1999-09-15
US20020028839A1 (en) 2002-03-07
US20060223867A1 (en) 2006-10-05
BE1011980A5 (fr) 2000-03-07

Similar Documents

Publication Publication Date Title
ITMI990375A1 (it) Trattamento del cancro co epotiloni
AR028476A1 (es) Tratamiento del cancer
KR100695846B9 (ko) 암 치료
FI20000863A0 (fi) Uusi hoitomenetelmä
DE69929047D1 (de) Haarbehandlungsmittel
DE59913141D1 (de) Blutbehandlungsgerät
DE69936741D1 (de) Wäschebehandlung
DE69933079D1 (de) Katheter
NO20005179D0 (no) Medikament behandling
NO20032122L (no) Forbedret behandling
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
DE69912327D1 (de) Katheter
NO20013337D0 (no) Ny behandling
BR0012043B1 (pt) composiÇço de tratamento de cabelo.
DE60022086D1 (de) Wasserbehandlung
GB0026015D0 (en) Cancer treatment
ZA200203166B (en) Treatment of cancer.
GB9804361D0 (en) Cancer treatment
DE69912763D1 (de) Behandlungsanlage
GB9903035D0 (en) Treating cancer
DE50003427D1 (de) Rinnenkörper
GB2334579B (en) Treating cancer
GB9820000D0 (en) Cancer treatment
GB9818023D0 (en) Cancer treatment
GB9908176D0 (en) Cancer treatment